COVID-19 trials registries data warehouse

http://en.irct.ir/trial/61974

Afshin Zarghi

mpd@sbmu.ac.ir

2022-02-28

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

Patients between 18 and 100 years old Laboratory confirmed COVID-19 with RT-PCR Be in severe stage of the disease Have signed the consent to participate in the study

Acute or chronic renal failure (Increase in creatinine by more than 3.0 in the last 48 hours or GFR less than 30 mL/min) Liver failure (more than 5-fold increase in liver enzymes in asymptomatic patients or more than 3-fold increase in liver enzymes in symptomatic patients or Child Pugh C, D) Hypersensitivity reaction to tocilizumab or baricitinib with severe extravasation and symptoms of anaphylactic shock Mild stage of the disease Pregnant and lactating patients Patients who have been intubated Patients who are expected to die in the next 48 hours

2

Shahid Beheshti University of Medical Sciences

18

100

Iran

Severe disease at enrollment

6: Severe disease at enrollment

60

28 days mortality Need for intubation

Phase 3

[{"arm_notes": "", "treatment_id": 1299, "treatment_name": "Tocilizumab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2180, "treatment_name": "Baricitinib+tocilizumab", "treatment_type": "Kinase inhibitors+interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}]